Antonio Gotto

Q: What Schools Are Affiliated With Antonio Gotto

Antonio Gotto is affiliated with the following schools: Harvard University, University of North Texas Health Science Center, University of Milan, Weill Cornell Medicine, Vanderbilt University, Baylor College of Medicine, Cornell University

Antonio Gotto's AcademicInfluence.com Rankings

Antonio Gotto

Philosophy

#4749

World Rank

#7377

Historical Rank

#1333

USA Rank

Logic

#2153

World Rank

#3081

Historical Rank

#542

USA Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Antonio Gotto Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Antonio M. Gotto, Jr. was Dean of Weill Medical College of Cornell University. He was succeeded by Laurie H. Glimcher in January 2012. Prior to his appointment in 1997, Gotto was chairman of the department of internal medicine at Baylor College of Medicine for 20 years, where he collaborated extensively with Michael DeBakey. Gotto is best known for his research into blood lipids. As administrator, he presided over an enormous growth at Cornell, an affiliation with Houston Methodist Hospital when it separated from Baylor, and a deepening of Cornell's longtime affiliation with New York Hospital following its merger with Columbia Presbyterian to form the New York-Presbyterian Hospital.

(See a Problem?)

Antonio Gotto's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

K/DOQI clinical practice guidelines for chronic kidney disease (2002) (8858)
Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. (1998) (5478)
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. (2008) (4914)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. (2005) (3308)
K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. (2003) (2521)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials (2010) (1770)
Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. (2001) (1665)
Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study. (1997) (1386)
K/DOQI Clinical Practice Guidelines on Hypertension and Antihypertensive Agents in Chronic Kidney Disease (2004) (1050)
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial (2009) (989)
Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography. (1986) (975)
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials (2009) (781)
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. (2007) (767)
AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. (2001) (723)
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. (2009) (695)
AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. (2001) (628)
Safety of anacetrapib in patients with or at high risk for coronary heart disease. (2010) (610)
Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (2000) (607)
The evolving role of statins in the management of atherosclerosis. (2000) (606)
HDL Cholesterol and Protective Factors in Atherosclerosis (2004) (589)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials (2015) (559)
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (2004) (556)
Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. (2012) (532)
Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. (2014) (513)
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials (2019) (377)
Preventing heart attack and death in patients with coronary disease. (1995) (371)
Inflammation in Atherosclerosis and Implications for Therapy (2004) (344)
Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). (1997) (340)
Effects of cyclosporine therapy on plasma lipoprotein levels. (1989) (265)
Relation of diet to high-density-lipoprotein cholesterol in middle-aged marathon runners, joggers, and inactive men. (1980) (238)
Disturbances in lipid and lipoprotein metabolism (1978) (238)
A Randomized Trial of a Strategy for Increasing High-Density Lipoprotein Cholesterol Levels: Effects on Progression of Coronary Heart Disease and Clinical Events (2005) (236)
Assessing low levels of high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report and update. (2004) (229)
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. (2002) (228)
Triglyceride as a risk factor for coronary artery disease. (1998) (227)
Comparison of 2-year weight loss trends in behavioral treatments of obesity: diet, exercise, and combination interventions. (1996) (222)
Update on Statins: 2003 (2004) (215)
Statin Therapy and Outcome After Ischemic Stroke: Systematic Review and Meta-Analysis of Observational Studies and Randomized Trials (2013) (203)
Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. (1999) (202)
Levels of soluble cell adhesion molecules in patients with dyslipidemia. (1996) (198)
Benefits of statins in elderly subjects without established cardiovascular disease: a meta-analysis. (2013) (196)
27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 1. Pathogenesis of coronary disease: the biologic role of risk factors. (1996) (196)
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial (2010) (191)
Preventing coronary artery disease by lowering cholesterol levels: fifty years from bench to bedside. (1999) (180)
Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis (2013) (174)
Effects of stress management training and dietary changes in treating ischemic heart disease (1983) (173)
Residual macrovascular risk in 2013: what have we learned? (2014) (157)
A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. (2005) (156)
A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. (2000) (151)
Relationship between Plasma Lipid Concentrations and Coronary Artery Disease in 496 Patients (1977) (144)
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. (2001) (135)
Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. (2007) (130)
Monocyte‐to‐HDL‐cholesterol ratio as a prognostic marker in cardiovascular diseases (2018) (130)
Hyperlipidemia after heart transplantation: report of a 6-year experience, with treatment recommendations. (1992) (130)
Effects of stress management training and dietary changes in treating ischemic heart disease. (1982) (129)
High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease. (2002) (124)
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials (2015) (123)
Low High-Density Lipoprotein Cholesterol as a Risk Factor in Coronary Heart Disease: A Working Group Report (2001) (123)
Triglyceride: the forgotten risk factor. (1998) (122)
Lowering LDL cholesterol: questions from recent meta-analyses and subset analyses of clinical trial DataIssues from the Interdisciplinary Council on Reducing the Risk for Coronary Heart Disease, ninth Council meeting. (1999) (109)
Cholestyramine in type II hyperlipoproteinemia. A double-blind trial. (1973) (99)
Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. (1992) (95)
Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib. (2009) (94)
Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association. (2017) (91)
Risk reduction. (2020) (91)
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): efficacy and tolerability of long-term treatment with lovastatin in women. (2000) (90)
Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system (1998) (90)
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia (2020) (90)
Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. (2000) (88)
Effect of alcohol intake on high-density lipoprotein cholesterol levels in runners and inactive men. (1983) (87)
Lipid lowering, regression, and coronary events. A review of the Interdisciplinary Council on Lipids and Cardiovascular Risk Intervention, Seventh Council meeting. (1995) (84)
Cholesterol management in theory and practice. (1997) (83)
Two-year follow-up of patients treated with a very-low-calorie diet and exercise training. (1988) (83)
Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease. (2014) (83)
PCSK9 and inflammation: a review of experimental and clinical evidence. (2019) (82)
Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. (2000) (81)
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis. (1984) (80)
Design & rationale of the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (1997) (80)
Antioxidants, statins, and atherosclerosis. (2003) (80)
Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration. (1995) (79)
Health family trees: a tool for finding and helping young family members of coronary and cancer prone pedigrees in Texas and Utah. (1988) (78)
Safety and statin therapy: reconsidering the risks and benefits. (2003) (78)
Pleiotropic effects of statins: do they matter? (2001) (78)
Management of cardiovascular risk: the importance of meeting lipid targets. (2012) (77)
Diet and health. (1984) (77)
Effect of moderate alcohol consumption on hypertriglyceridemia: a study in the fasting state. (1999) (76)
Rationale for treatment. (1991) (75)
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. (2006) (73)
Effect of exercise training on plasma high-density lipoprotein cholesterol in coronary disease patients. (1981) (68)
Drug treatment of hyperlipidemia. (1976) (67)
Plasma Homocysteine Concentration, Statin Therapy, and the Risk of First Acute Coronary Events (2002) (66)
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. (2001) (63)
Treatment of symptomatic peripheral atherosclerotic disease with a rotational atherectomy device. (1989) (61)
Serum cholesterol. Doing the right thing. (1993) (59)
Statins, cardiovascular disease, and drug safety. (2006) (59)
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. (2010) (58)
Evolving concepts of dyslipidemia, atherosclerosis, and cardiovascular disease: the Louis F. Bishop Lecture. (2005) (58)
Review of primary and secondary prevention trials with lovastatin, pravastatin, and simvastatin. (2005) (57)
Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib[S] (2013) (55)
Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). (2009) (55)
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. (2004) (55)
Behavioral treatment of obesity: Results and limitations (1982) (54)
Interactions of the major risk factors for coronary heart disease. (1986) (53)
Plasma lipids as collateral risk factors in coronary artery disease--a study of 371 males with chest pain. (1978) (53)
Lipid management in diabetic patients: lessons from prevention trials. (2002) (52)
Effects of lipid lowering therapy on progression of coronary and carotid artery disease. (1997) (52)
Management of dyslipidemia. (2002) (52)
Role of C-reactive protein in coronary risk reduction: focus on primary prevention. (2007) (51)
Jeremiah Metzger Lecture: cholesterol, inflammation and atherosclerotic cardiovascular disease: is it all LDL? (2011) (50)
A new fluorimetric procedure for the detection and quantitation of organic compounds in thin-layer chromatography. (1974) (50)
Recent clinical studies of the effects of lipid-modifying therapies. (2012) (48)
Statin Intolerance: the Clinician’s Perspective (2015) (48)
Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. (1992) (48)
Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis (2009) (48)
The metabolic syndrome: a call to action. (2006) (47)
Lipid-modifying activity of curcuminoids: A systematic review and meta-analysis of randomized controlled trials (2019) (47)
The 9p21 susceptibility locus for coronary artery disease and the severity of coronary atherosclerosis (2009) (45)
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin (2002) (45)
Pharmacotherapies for lipid modification: beyond the statins (2013) (44)
Anti‐adipogenic action of pitavastatin occurs through the coordinate regulation of PPARγ and Pref‐1 expression (2007) (44)
The hypertriglyceridemias: risk and management. Introduction. (1991) (44)
Recommendations for the treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis of the American Heart Association. (1984) (43)
The Heart Protection Study: expanding the boundaries for high-risk coronary disease prevention. (2003) (43)
Lipoprotein lipase gene mutations, plasma lipid levels, progression/regression of coronary atherosclerosis, response to therapy, and future clinical events. Lipoproteins and Coronary Atherosclerosis Study. (1999) (43)
Statin therapy: where are we? Where do we go next? (2001) (42)
Lipids, Safety Parameters, and Drug Concentrations After an Additional 2 Years of Treatment With Anacetrapib in the DEFINE Study (2014) (42)
Weight control and nutrition education programs in occupational settings. (1980) (41)
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials. (2020) (41)
Hyperlipidemia following heart transplantation: natural history and intervention with mevinolin (lovastatin). (1987) (40)
Lipoprotein(a) and apolipoprotein changes after cardiac transplantation. (1991) (40)
Limitations of behavioral treatment of obesity: Review and analysis (1981) (40)
AHA consensus panel statement. Preventing heart attack and death in patients with coronary disease. The Secondary Prevention Panel. (1995) (37)
Undertreatment of dyslipidemia in peripheral arterial disease and other high-risk populations: an opportunity for cardiovascular disease reduction (2002) (37)
Treating hypercholesterolemia: Looking forward (2003) (36)
Effects of Beef and Chicken Consumption on Plasma Lipid Levels in Hypercholesterolemic Men (1994) (36)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes. (2004) (35)
Effect of lovastatin on cardiovascular resource utilization and costs in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). AFCAPS/TexCAPS Research Group. (2000) (35)
Effects of a low cholesterol eating plan on plasma lipids: results of a three-year community study. (1983) (35)
Hypertriglyceridemia: risks and perspectives. (1992) (34)
The Multiple Risk Factor Intervention Trial (MRFIT). A return to a landmark trial. (1997) (33)
Response of free-living adults to behavioral treatment of obesity: Attrition and compliance to exercise (1993) (33)
Effects of beef and chicken consumption on plasma lipid levels in hypercholesterolemic men. (1994) (33)
The efficacy of lay CPR instruction: an evaluation. (1977) (32)
Currently available hypolipidaemic drugs and future therapeutic developments. (1995) (31)
Dyslipidemia and the vulnerable plaque. (2002) (31)
The Lipoprotein and Coronary Atherosclerosis Study (LCAS): design, methods, and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia. (1996) (30)
Statin therapy and the elderly: SAGE advice? (2007) (30)
Cardiologist's role in improving glucose control and global cardiovascular risk in patients with type 2 diabetes mellitus. (2007) (30)
Implications from the Air Force/Texas Coronary Atherosclerosis Prevention Study for the Adult Treatment Panel III guidelines. (2005) (29)
Management of hypertriglyceridemic patients. A. Treatment classifications and goals. (1991) (28)
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriocslerosis. (1984) (26)
Plasma lipid changes in the normal population following behavioral treatment. (1979) (26)
Ongoing clinical trials of statins. (2001) (26)
Antihyperlipidaemic Agents (1994) (26)
Risk factor modification: rationale for management of dyslipidemia. (1998) (26)
The cardiology patient page. Statins: powerful drugs for lowering cholesterol: advice for patients. (2002) (25)
Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. (1996) (25)
Assessing the benefits of lipid-lowering therapy. (1998) (25)
Results of recent large cholesterol-lowering trials and implications for clinical management. (1997) (25)
Application of the National Cholesterol Education Program and joint European treatment criteria and clinical benefit in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (2000) (25)
Lipid management in patients at moderate risk for coronary heart disease: insights from the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (1999) (25)
Drug Insight: the role of statins in combination with ezetimibe to lower LDL cholesterol (2006) (25)
Atherosclerosis: Evolving vascular biology and clinical implications. Introduction (2004) (24)
The evolution of European guidelines: changing the management of cholesterol levels. (2006) (24)
Effects of anacetrapib on plasma lipids in specific patient subgroups in the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) trial. (2015) (24)
Psychological profile of college students who use smokeless tobacco. (1993) (23)
Lipid-lowering therapy for the primary prevention of coronary heart disease. (1999) (23)
Occupational screenings: recruitment from private industry. (1982) (23)
Structure and conformational analysis of lipid-associating peptides of apolipoprotein B-100 produced by trypsinolysis (1989) (23)
Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Liposorber Study Group. (1998) (22)
Effect of fibrates on glycemic parameters: A systematic review and meta‐analysis of randomized placebo‐controlled trials (2017) (22)
Risks and benefits of continued aggressive statin therapy (2003) (22)
NCEP ATP III guidelines incorporate global risk assessment. (2003) (21)
Blood lipids and coronary heart disease. (1978) (21)
Dietary treatment of type IV hyperlipoproteinemia. (1977) (21)
A low-cholesterol menu in a steak restaurant. (1979) (21)
Lipid risk factors and the regression of atherosclerosis. (1995) (20)
Safety of inhibition of cholesteryl ester transfer protein with anacetrapib: the DEFINE study (2012) (20)
Effect of soy isoflavone supplementation on plasma lipoprotein(a) concentrations: A meta-analysis. (2017) (19)
Cholesterol intake and serum cholesterol level. (1991) (19)
Diversity Efforts, Admissions, and National Rankings: Can We Align Priorities? (2014) (18)
Baseline characteristics of subjects in the Lipoprotein and Coronary Atherosclerosis Study (LCAS) with fluvastatin. (1994) (17)
Statins and C-reactive protein: considering a novel marker of cardiovascular risk. (2002) (17)
HDL functionality in familial hypercholesterolemia: effects of treatment modalities and pharmacological interventions. (2018) (17)
Statin Therapy and Outcome After Ischemic Stroke (2013) (17)
Choosing the right lipid-regulating agent. A guide to selection. (1996) (16)
Past, present, and future standards for management of dyslipidemia. (2004) (16)
Over‐the‐counter statins and cardiovascular disease prevention: Perspectives, challenges, and opportunities (2005) (16)
Treatment of HIV-associated dyslipidemia: a role for omega-3 fatty acids. (2007) (16)
The case for over-the-counter statins. (2004) (15)
Lipoprotein metabolism and the etiology of hyperlipidemia. (1988) (15)
Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials (2022) (15)
Some reflections on arteriosclerosis: past, present, and future. (1985) (15)
Structure and orientation of Apo B-100 peptides into a lipid bilayer (1994) (14)
Insights on treating an over-the-counter-type subgroup: data from the Air Force/Texas Coronary Atherosclerosis Prevention Study Population. (2000) (14)
Ileal bypass in the treatment of hyperlipoproteinaemia. (1973) (14)
Regression of atherosclerosis. (1981) (14)
Soup consumption as a behavioral weight loss strategy. (1986) (13)
Reducing the risk for stroke in patients with myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. (2002) (13)
Dyslipidemia and Atherosclerosis A Forecast of Pharmaceutical Approaches (1993) (13)
Prevalence of the apolipoprotein E Arg145Cys dyslipidemia at-risk polymorphism in African-derived populations. (2014) (13)
Prognostic and therapeutic significance of low levels of high-density lipoprotein cholesterol: current perspectives. (1999) (13)
Calcium channel blockers and the prevention of atherosclerosis. (1990) (13)
Comparing a novel machine learning method to the Friedewald formula and Martin-Hopkins equation for low-density lipoprotein estimation (2020) (13)
Establishing the benefit of statins in low-to-moderate--risk primary prevention: the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). (2007) (13)
The diagnosis and management of hyperlipidemia. (1986) (13)
Guidelines for the management of dyslipidaemia (2006) (13)
The Living Heart (1977) (13)
The Living Heart (1977) (13)
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Baseline Characteristics and Comparison with USA Population (2000) (12)
Heart disease in the assessment and treatment of hypercholesterolemia: coronary artery disease and other atherosclerotic disease, family history, and left ventricular hypertrophy. (1994) (12)
Diet, nutrition, and heart disease. (1986) (12)
Over-The-Counter Statins Are Worth Considering in Primary Prevention of Cardiovascular Disease (2006) (12)
Analysis of the carbohydrate composition of glycoproteins by high-performance liquid chromatography (1990) (12)
Current and future therapeutic approaches to hyperlipidemia. (1996) (11)
The benefits of statin therapy—what questions remain? (2005) (11)
Drugs affecting lipid metabolism : risk factors and future directions (1996) (10)
Apolipoprotein C-II deficiency revisited. (1984) (10)
The American Journal of Cardiology: Introduction (2001) (10)
Hyperlipidemia: perspectives in diagnosis and treatment. (1995) (10)
Eligibility for lipid-lowering drug therapy in primary prevention: how do the Adult Treatment Panel II and Adult Treatment Panel III Guidelines compare? (2002) (10)
Choosing the Right Lipid-Regulating Agent (1996) (10)
Cardiovascular risk factors in a tri-ethnic population: Houston, Texas 1972-1975. (1981) (10)
Postprandial hyperlipidemia. (1991) (10)
Plasma lipids and other cardiovascular risk factors in Costa Rican adolescents. (2000) (10)
Postmenopausal hormone-replacement therapy, plasma lipoprotein[a], and risk for coronary heart disease. (1994) (10)
Diet and cholesterol guidelines and coronary heart disease. (1989) (9)
Merits and potential downsides of the 2013 ACC/AHA cholesterol management guidelines. (2014) (9)
Once-daily, extended-release gemfibrozil in patients with dyslipidemia. The Lopid SR Work Group I. (1993) (9)
The Cholesterol Wars: The Cholesterol Skeptics vs the Preponderance of Evidence (2008) (9)
Drug development report (6): Pravastatin: A hydrophilic inhibitor of cholesterol synthesis (1990) (9)
Building a Transcontinental Affiliation: A New Model for Academic Health Centers (2005) (9)
A New Approach for Evaluating Risk Factors in Coronary Artery Disease: A Study of Lipid Concentrations and Severity of Disease in 1847 Males (1980) (9)
The Lipoprotein and Coronary Atherosclerosis Study (LCAS) in context: assessing the benefits of lipid-lowering therapy. Introduction. (1998) (8)
High-density lipoprotein cholesterol: an updated view. (2001) (8)
Effect of polyunsaturated versus saturated fat on LDL metabolism in normal subjects (1976) (8)
Primary and secondary prevention of coronary artery disease (1992) (8)
Improving lipid goal attainment: is it enough? (2009) (8)
Comparative effects of atenolol versus celiprolol on serum lipids and blood pressure in hyperlipidemic and hypertensive subjects. (1993) (8)
Primary prevention of coronary heart disease: where do we go from here? (2001) (8)
Prevention of coronary heart disease in 1994: evidence for intervention. (1994) (8)
2. Postprandial hyperlipidemia (1991) (7)
Editorial: Diet and Coronary Heart Disease The Statistical Analysis of Risk (1981) (7)
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials. (2022) (7)
Extending the benefit of lipid-regulating therapy to primary prevention. (1995) (7)
Lipid-Modifying and Antiatherosclerotic Drugs (2009) (7)
Stain therapy and reduced incidence of stroke. Implications of cholesterol-lowering therapy for cerebrovascular disease. (1997) (7)
Evaluating commercial weight-loss clinics. (1982) (7)
Are low-cholesterol diets expensive? (1979) (6)
Developing and evaluating audiovisual media for dietary education. (1978) (6)
Rosuvastatin is more effective than atorvastatin at improving the lipid profiles of patients with primary hypercholesterolaemia (2001) (6)
Primary type V hyperlipoproteinemia in childhood. (1977) (6)
Is atherosclerosis reversible? (1979) (6)
Treatment of hyperlipidemia. (1986) (6)
Targeting high-risk young patients for statin therapy. (2004) (6)
C-reactive protein and coronary heart disease. (2004) (6)
Lipid and lipoprotein abnormalities in renal disease. (1976) (6)
Is it appropriate to make statins available over the counter? Over-the-counter statins are worth considering in primary prevention of cardiovascular disease. (2006) (6)
Intensive Lipid Lowering in Elderly Patients. (2019) (6)
Overview of current issues in management of dyslipidemia. (1993) (5)
On-treatment Levels of HDL-C and the Ratio of LDL-C/HDL-C as Predictors of Cardiovascular Events in the Treating to New Targets (TNT) Study (2006) (5)
Primary structure of Beijing duck apolipoprotein A-1 (1993) (5)
Normolipidemic Dyslipoproteinemia in Patients with Coronary Artery Disease (1989) (5)
Coronary events with lipid-lowering therapy: The AFCAPS/TexCAPS trial [1] (multiple letters) (1999) (5)
Clinical diagnosis of hyperlipoproteinemia. (1983) (5)
The Editor's Roundtable: the metabolic syndrome. (2007) (5)
Therapeutic intervention for hypercholesterolemia (1992) (5)
apo-C-II deficiency: a new mutant. (1978) (5)
Apolipoprotein mutations and markers for coronary heart disease (1990) (5)
Erratum: The lipoprotein and coronary atherosclerosis study (LCAS): Design, methods and baseline data of a trial of fluvastatin in patients without severe hypercholesterolemia (Controlled Clinical Trials, 1996; 17: 550-583) (1997) (5)
ELISA quantitation of apolipoproteins in plasma lipoprotein fractions: ApoE in apoB-containing lipoproteins (Lp B:E) and apoB in apoE-containing lipoproteins (Lp E:B) (1995) (5)
Lipid-regulating and antiatherosclerotic therapy: current options and future approaches. (1996) (5)
Variability in the ABCA1 gene but not HMG-CoA reductase predicts low-density lipoprotein lowering effects of statins (2003) (5)
Atherosclerosis: Its Pathogenesis and the Role of Cholesterol. Atherosclerosis Reviews, vol. 23 (1991) (5)
Apolipoproteins and metabolism in atherosclerosis. (1990) (5)
Does torcetrapib reduce the progression of atherosclerotic disease? (2007) (4)
A trilogy of primary prevention statin trials. Panel discussion. (2007) (4)
Preventing heart attack and death in patients with coronary disease. Endorsed by the board of trustees of the American College of Cardiology. (1996) (4)
Integrated Measure for Atherogenic Lipoproteins in the Modern Era: Risk Assessment Based on Apolipoprotein B. (2016) (4)
Does low cholesterol cause death? (1993) (4)
U.S.A. perspective (1992) (4)
Dyslipidaemia in Clinical Practice (2001) (4)
Abstract 9649: Lipid-modifying Effects of Anacetrapib in Patients with Lower versus Higher Baseline Levels Of HDL-C, LDL-C, And TG: Pre-Specified Subgroup Analyses of the DEFINE (Determining the Efficacy and Tolerability of CETP INhibition with AnacEtrapib) Trial (2011) (4)
How do we achieve optimal cardiovascular risk reduction? (2001) (4)
When Clinical Trials Fail to Address Treatment Gaps: The Failure of Niacin-Laropiprant to Reduce Cardiovascular Events (2013) (4)
Directions of atherosclerosis research in the 1980s and 1990s (1984) (4)
Cellular and Molecular Biology of Atherosclerosis (2011) (4)
Abstract 15035: Effects on Lipids and Safety Following Cessation of Treatment with Cholesteryl Ester Transfer Protein Inhibitor Anacetrapib in Patients with or at High Risk for Coronary Heart Disease (2011) (4)
MPSA short communications (1988) (3)
Low-Density Lipoprotein Cholesterol and Cardiovascular Risk Reduction: How Low Is Low Enough Without Causing Harm? (2018) (3)
Atherosclerosis risk classification with computed tomography angiography: A radiologic-pathologic validation study. (2022) (3)
Profiles in cardiology: Michael E. DeBakey (1991) (3)
Highly Conserved Amino Acid Residues in Apolipoprotein A1 Discordantly Induce High Density Lipoprotein Assembly In Vitro and In Vivo. (2020) (3)
The case for aggressive lipid regulation. (1997) (3)
Clinical investigations of the arrest and reversal of coronary artery disease. (1995) (3)
[Women and ischemic cardiopathy]. (1989) (3)
Obesity: A new approach to an old problem (1980) (3)
Dietary aspects of hyperlipidemia. (1973) (3)
Multiple Risk Factors in Cardiovascular Disease (1992) (3)
Atherosclerosis: Pathogenesis, Morphology, and Risk Factors (2007) (3)
Triglycerides : the role in diabetes and atherosclerosis (1991) (3)
Comprehensive management of high risk cardiovascular patients (2007) (3)
Introduction: Using a multifactorial approach in assessing and treating the high-risk patient (2003) (3)
Prudent eating after 40. Relationship of diet to blood lipids and coronary heart disease. (1974) (3)
Atherosclerotic cardiovascular disease: current prospectives. (1976) (3)
Aggressive treatment aimed at raising high-density lipoprotein cholesterol in stable patients with angiographically evident coronary disease prevents stenosis progression and reduces cardiovascular events (2003) (3)
Lipid-lowering trials: what have they taught us about morbidity and mortality? (1995) (3)
Erratum: Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis ( (Journal of the American College of Cardiology ( 2013) 62 (2090-2099) (2014) (3)
Effects of pravastatin in heart transplant recipients: implications of Kobashigawa et al. (1995) (3)
FACTORS THAT INFLUENCE BEMPEDOIC ACID-MEDIATED REDUCTIONS IN HIGH-SENSITIVITY C-REACTIVE PROTEIN: ANALYSIS OF POOLED PATIENT-LEVEL DATA FROM PHASE 3 CLINICAL TRIALS (2020) (2)
Effect of bempedoic acid on uric acid and gout in 3621 patients with hypercholesterolemia: pooled analyses from phase 3 trials (2020) (2)
Peroxisome Proliferator Activated Receptors: From Basic Science to Clinical Applications (2002) (2)
Citation classics in lipid measurement and applications. (1998) (2)
7. Management of hypertriglyceridemic patients (1991) (2)
Hypertriglyceridemia as a vascular risk factor (1991) (2)
Results of Lipid-Lowering Trials in the Elderly and a Look to the Future. (1996) (2)
Dietary and behavioral treatment of hyperlipidemia. (1978) (2)
Lipids and atherosclerosis risk: A status report (1998) (2)
Cholesterol and total mortality (1992) (2)
Case 1: a patient with elevated low-density lipoprotein cholesterol. (2000) (2)
Cholesteryl ester and triacylglycerol fatty acids in type V hyperlipidemia (1979) (2)
Twenty-five years of statins: where do we go from here? (2015) (2)
Multiple risk factors in cardiovascular disease : vascular and organ protection (1995) (2)
Multiple risk factors in cardiovascular disease : strategies of prevention of coronary heart disease, cardiac failure, and stroke (1998) (2)
A symposium: triglycerides as a vascular risk factor: a global forum. Introduction. (1992) (2)
Treatment of patients with mild to moderate hypercholesterolemia: Lipoprotein and Coronary Atherosclerosis Study (LCAS) (1998) (2)
Extreme hypercholesterolemia in cholestatic sarcoidosis due to lipoprotein X: Exploring the cholesterol gap (2018) (2)
The editor's roundtable: JUPITER follow-up. (2011) (2)
Chapter 15. Drug Therapy of Dyslipoproteinemias (1989) (2)
Chelation therapy in 1984. (1984) (2)
Coronary and Cerebral Vascular Disease: A Practical Guide to Management of Patients With Atherosclerotic Vascular Disease of the Heart and Brain (1989) (2)
13. Importance of HDL from recent clinical trials: how good is the evidence? (1999) (2)
Emerging perspectives on lipid management: international approaches and global challenges. (2001) (2)
Lesion progression, regression, and stability with fluvastatin in the lipoprotein and coronary atherosclerosis study (1998) (2)
Bempedoic Acid and Glycemic Control: A Pooled Analysis of 4 Phase 3 Clinical Trials (2020) (2)
Biomedical research priorities in the 1970's. (1977) (1)
Reduction in C-Reactive Protein and Low-Density Lipoprotein Cholesterol and Cardiovascular Event Rates After Initiation of Rosuvastatin: A Prospective Study of the justification for the Use of Statins in Prevention: An Intervention, Trial Evaluating Rosuvastatin Trial (2009) (1)
Should lipid-lowering drugs be part of initial therapy in the secondary prevention of CHD? (1996) (1)
Atherosclerosis V (1980) (1)
Weill Cornell Medicine: A History of Cornell's Medical School (2016) (1)
The transport of plasma lipids: basic and clinical research and relationship to coronary heart disease. (1983) (1)
Tribute to Dr. Michael E. DeBakey (2010) (1)
Preventing coronary disease in women: brief observations from the clinical data. (1998) (1)
Cholesteryl ester transfer protein variants are associated with plasma levels of high-density lipoprotein cholesterol but not the severity or progression of coronary atherosclerosis or response to therapy (2003) (1)
Atherosclerosis VI (1983) (1)
Treatment of severe dyslipoproteinemia in the prevention of coronary heart disease - 3: 3rd international symposium, Munich, October 17-18, 1990. (1992) (1)
Statins: Risk-Benefits and Role in Treating Dyslipidemias (2015) (1)
The low-density lipoprotein hypothesis: Proven again with the Improved Reduction of Outcomes: Vytorin Efficacy International Trial. (2015) (1)
A symposium : impact of multiple risk factors on coronary artery disease : beyond total cholesterol (1998) (1)
Lipid Metabolism and Menopause (1994) (1)
185-OR: Efficacy and Safety of Bempedoic Acid in Patients with Diabetes, Prediabetes, and Normoglycemia: Analysis of Pooled Patient-Level Data from Four Phase 3 Clinical Trials (2020) (1)
Obesity, risk factor no. 1 (1978) (1)
Update on the evaluation and management of cardiovascular risk. Introduction. (2012) (1)
Current Concepts of Hyperlipoproteinemia (1977) (1)
Michael E. DeBakey. (1991) (1)
AHA Conference Report on Cholesterol. (1989) (1)
Multiple Risk Factors in Cardiovascular Disease (1998) (1)
Dyslipidemia & Atherosclerosis Essentials (2016) (1)
Type V hyperlipoproteinaemia. (1973) (1)
Cholesterol levels in young adults: screen and intervene? (1994) (1)
Does post-menopausal hormone-replacement therapy increase risk for breast cancer? A perspective on the findings of the Nurses' Health Study. (1995) (1)
Lipid lowering and coronary risk. (1996) (1)
Etiology, diagnosis, and treatment of the lipid transport disorders (1988) (1)
Review of clinical trial data reaffirms safety of statin therapy. (2002) (1)
Statins: Do They Have Beneficial Effects Over and Above Their Actions on Lipids? (2020) (1)
Beta-apoprotein sufficiency and function. (1969) (1)
Issues and anwers: therapeutIc options (1992) (0)
Circulation Research provides a medium for bringing together basic research on the cardiovascular sys- tem from various disciplines including biology, biochemistry, biophysics, morphology, pathology, physiology, and pharmacology. The Journal also will accept for publication manuscripts on clinical r (1977) (0)
Abstract: S4-1 LDL, CRP, AND CORONARY HEART DISEASE REDUCTION (2009) (0)
Clinical assessment of dyslipidaemia (2006) (0)
[Children and dyslipemia]. (1990) (0)
Coronaries and diet (1984) (0)
Structure-Function Relationships in the Plasma Lipoproteins (1983) (0)
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. (2005) (0)
No deception in symposium supplement (1994) (0)
Dietary and lifestyle factors in dyslipidaemia (2006) (0)
Women and Coronary Heart Disease (2007) (0)
Case 2: a patient with low levels of high-density lipoprotein cholesterol. (2000) (0)
The DeBakey Center. (1980) (0)
AIM-HIGH and HDL (2011) (0)
Treatment of the Hyperlipidemic States (2015) (0)
Genetic deletion of LDL receptor impairs mouse macrophage ABCA1 expression and cholesterol efflux: A new SREBP‐1 dependent mechanism (2007) (0)
2. Clinical Innovation and a Historic Partnership (2016) (0)
A symposium: The significance of high-density lipoprotein cholesterol in the prevention of coronary artery disease: Introduction (1990) (0)
Serum opacity factor normalizes dysfunctional HDL phenotype in SRB1 -/- mice (2021) (0)
Impact of multiple risk factors on coronary artery disease: beyond total cholesterol. Introduction. (1998) (0)
Pioglitozone inhibits the progression, but does not reverse development of atherosclerosis, in LDL receptor‐deficient mice (2006) (0)
Hypercholesterolemia: new findings and clinical applications. Introduction. (1991) (0)
Should patients with combined hyperlipidemia receive statin–fibrate combination therapy? (2005) (0)
Comparison of Levels of Large and Small High-Density Lipoprotein Cholesterol in Asian Indian Men Compared With Caucasian Men in the Framingham Offspring Study (2004) (0)
How Do We Aclueve Optimal Cardiovascular Risk Reduction? (2009) (0)
Therapeutic Intervention in Diabetic Dyslipidemia (1995) (0)
Quantitative determination of lipoprotein particles containing apolipoprotein B and E in plasma by an enzyme-linked immunosorbent assay (1994) (0)
5. Postwar Boom (2016) (0)
Clinical Approaches to Dyslipidemia (1994) (0)
Defining the Clinical Benefit of Cholesterol Lowering (1996) (0)
[HDL cholesterol profile in 1988]. (1989) (0)
Pathophysiology of plasma lipids (2006) (0)
4. The Medical School in Wartime (2016) (0)
Dietary Treatment of Hyperlipidemia (1994) (0)
SITE-SPECIFIC ALTERATIONS OF APO B-100 ARE OBSERVED IN THE COPPER-CATALYZED OXIDATION OF LOW DENSITY LIPOPROTEINS (LDL). 1458 (1996) (0)
EFFECTS OF LONGER-TERM TREATMENT WITH ANACETRAPIB ON SAFETY PARAMETERS, LIPIDS, AND PLASMA DRUG CONCENTRATIONS IN THE DEFINE TRIAL (2014) (0)
High Blood Cholesterol and Cardiovascular Deaths in Women (2005) (0)
Hot Topics in Cardiology: Foreword (2009) (0)
7. A Decade of Malaise (2016) (0)
Risk Factors and Prevention, Including Hyperlipidemia (2013) (0)
GENERAL DISCUSSION (1980) (0)
Screening for dyslipidaemia (2006) (0)
Should hyperlipidemia be treated? Available agents and clinical results. (1978) (0)
In memoriam: Robert I. Levy 1937-2000. (2001) (0)
The editor's roundtable: Closing the clinical practice gap-using evidence-based treatments for managing lipids. (2011) (0)
Reducing cardiovascular risk in the metabolic syndrome: What we know and what we still need to know (2009) (0)
Cholestyramine in Type II Hyperlipoproteinemia (2020) (0)
Cholesterol-Lowering Clinical Trials: Where Do We Go From Here? (1992) (0)
Familial hypo-beta-lipoproteinemia (1978) (0)
Introduction (1992) (0)
8. Discord and Disrepair (2016) (0)
Subject Index Vol. 87,1996 (1996) (0)
Roundtable discussion. Achieving more aggressive low-density lipoprotein cholesterol lowering. (2000) (0)
Mo-PL1:1 Lipoproteins and the arterial wall (2006) (0)
Abstract: P1390 DESIGN OF THE DEFINE TRIAL: DETERMINING THE EFFICACY AND TOLERABILITY OF CETP INHIBITION WITH ANACETRAPIB (2009) (0)
Abstract 14248: Efficacy and Safety of Bempedoic Acid in Patients Who Cannot Tolerate Statins: Pooled Analysis of 4 Phase 3 Clinical Trials (2020) (0)
Management issues in primary care (2006) (0)
Activation of PPARα and PPARγ induce expression of the hepatic LDL receptor (2007) (0)
New options in lipid management--can we extend the benefits of current therapy? Introduction. (2002) (0)
Therapeutic impact of statin therapy in patients with low HDL cholesterol (1999) (0)
Abstract 12268: Efficacy of Bempedoic Acid: A Pooled Analysis of 4 Pivotal Phase 3 Clinical Trials (2019) (0)
Perspectives on Lipid-Lowering Therapy: Past and Present (1998) (0)
Clinical events: Vessel wall changes as surrogate market (1995) (0)
The HDL Quandary (2020) (0)
Effects of Chenodeoxycholic Acid (CD) Treatment on Endogenous Plasma Triglyceride (TG) Transport in Hyperlipoproteinemia (HLP) (1978) (0)
HMG-CoA Reductase Inhibitors (1996) (0)
2010 Clinical and Translational Research and Education Meeting: ACRT/SCTS Joint Annual Meeting (2010) (0)
In memoriam Donald S. Fredrickson, MD: 1924-2002. (2002) (0)
Cardiovascular disease, hyperlipidaemia and coagulation: Editorial overview (1990) (0)
Beating the Odds: The University of Massachusetts Medical School. A History, 1962–2012 by Ellen S. More (review) (2019) (0)
The lipid hypothesis. (1988) (0)
Yuichiro Goto (October 6, 1922–May 28, 2003) (2004) (0)
Lipids, lipoproteins, and apolipoproteins: biological end points and means of intervention (1984) (0)
Drugs affecting lipid metabolism: Effects on atherosclerosis progression and clinical events (1995) (0)
10. Forging Ahead in the Twenty-First Century (2016) (0)
Suffering, Medicine, and the Book of Job (2012) (0)
Challenges in clinical cardiology : a new era in lipid management : proceedings of a symposium (1998) (0)
In memoriam of Rodolfo Paoletti a tribute to a friend. (2021) (0)
Optimizing statin treatment. (2015) (0)
Selected for the National Lipid Association 2019 Scientific Sessions , May 16-19 , 2019 , Miami , FL 2019 Program Planners : (2019) (0)
Coronary Heart Disease Frequency in the Absence of Traditional Risk Factors (2001) (0)
Pharmacological management of dyslipidaemia (2006) (0)
Contrasting Effects on Plasma Lipoproteins of Intravenous Versus Oral Administration of a Triglyceride‐Phospholipid Emulsion (1975) (0)
Uncertainty of Survival (1976) (0)
Dietary aspects of hyperlipidemia1 (1973) (0)
Factors that Influence Bempedoic Acid-Mediated Reductions in High-sensitivity C reactive Protein: Analysis of Pooled Patient-level Data from Phase 3 Clinical Trials† (2020) (0)
9. Renaming and Rebirth (2016) (0)
[Non-pharmacologic treatment of hyperlipemia: diet and exercise]. (1989) (0)
3. A Move to Manhattan’s Upper East Side (2016) (0)
Therapeutic intervention for hypercholesterolemia. (1992) (0)
Walter Niles and the Cornell Pay Clinic. (2017) (0)
Congenital heart diseaseAbstractA Common PCSK9 Haplotype, Encompassing the E670G Coding Single Nucleotide Polymorphism, Is a Novel Genetic Marker for Plasma Low-Density Lipoprotein Cholesterol Levels and Severity of Coronary Atherosclerosis (2005) (0)
K/doqi Tm Disclaimer K/doqi Advisory Board Members K/doqi Tm Nutrition Work Group Membership Adult Work Group Members Pediatric Work Group Members Nkf-doqi Advisory Council* Nkf-doqi Steering Committee* Acronyms and Abbreviations List Abbreviation Term A1-ag A1-acid Glycoprotein Abw Ef Adjusted Edem (0)
Etude LCAS (Lipoprotein and Coronary Atherosclerosis Study) (1997) (0)
Increased Triglyceride Levels and Cardiovascular Disease (1992) (0)
In Memoriam: Yuichiro Goto, MD (October 6, 1992 - May 28, 2003). (2004) (0)
33 Approaches to Dyslipidemia (1994) (0)
2.C.1 New paradigms for reducing atherosclerosis and CHD: Now and into the 21st century (1997) (0)
mptomatic Peripheral sease with a Rotational therectomy Device (1989) (0)
Metabolic and clinical aspects of dyslipidemias: An overview (1989) (0)
Treatment of Ischemic Heart Disease-Reply (1983) (0)
Reduction of coronary events: evidence from clinical trials. (1995) (0)
Abstract: 14 SUMMARY OF AAMC GUIDELINES (2009) (0)
Impact of Insulin Resistance on Acute Major Coronary Events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS) (2002) (0)
Uncertainty of Survival: Cradle of Consciousness? (1976) (0)
Dedication of the Alkek Tower, Houston, Texas: Opening and closing remarks at the scientific lectures. (1979) (0)
Donald Sharp Fredrickson, MD (2003) (0)
Donald S. Fredrickson, MD (2002) (0)
History of Lipidology (2020) (0)
Cholesterol-CHD connection: evidence for the benefit of lipoprotein modification (1990) (0)
Interpreting lipid values from the clinical perspective (1985) (0)
Gustav Schonfeld, M.D.: 1934–2011. (2012) (0)
Targeted prevention for the higher-risk patient (1994) (0)
Erratum: Eligibility for lipid-lowering drug therapy in primary prevention (Circulation (2002) 105 (136-139)) (2002) (0)
Atherosclerosis Reviews. Volume 1. (1976) (0)
6. The Expansive 1960s (2016) (0)
Dyslipidaemia as a risk factor for cardiovascular disease (2006) (0)
Ethical issues and global health. (2008) (0)
Guidelines and global risk: a U.S. perspective (2002) (0)
Professor Jeremiah Stamler (1919-2022), "Father of Preventive Cardiology". (2022) (0)
Diet and heart disease: Responses to the findings concluded LRC-CPPT (1984) (0)
Structure/Functional Relationships in Serum Lipoproteins (1979) (0)
Preventing coronary disease in women (1998) (0)
Primary and secondary prevention of atherosclerosis and coronary heart disease (1987) (0)
Introduction to the volume on dedication of the National Heart and Blood Vessel Research and Demonstration Center. (1976) (0)
Contents, Vol. 87, 1996 (1996) (0)
20 Metabolism and Menopause (1994) (0)
Case 3: Insulin-dependent diabetes mellitus. (2000) (0)
Oxidation of β-casein by hypochlorite (HOC1) (1996) (0)
[Detection and treatment of lipid disorders]. (1988) (0)
The Second International Conference on Lipoprotein[a]: preface. (1994) (0)
Interdisciplinary Council Current and Future Approaches to Cardiovascular Risk Management: Introduction (2003) (0)
Endothelial and hepatic lipase gene polymorphisms are associated with plasma levels of high-density lipoprotein cholesterol in lipoprotein coronary atherosclerosis study (2003) (0)
Percent of Fat in Meat, Poultry and Seafood: Dr Gotto and Ms Scott Reply. (1985) (0)

This paper list is powered by the following services:

Other Resources About Antonio Gotto

en.wikipedia.org

What Schools Are Affiliated With Antonio Gotto?

Antonio Gotto is affiliated with the following schools:

Antonio Gotto's Academic­Influence.com Rankings